Perimenopause Treatment Algorithm by Line of Therapy

What Is Perimenopause and How Is It Diagnosed?

Perimenopause is the hormonally unstable transition period preceding menopause, marked by declining ovarian follicular reserve, rising FSH, and erratic estradiol levels. The STRAW+10 staging system, endorsed by the Endocrine Society and published in Climacteric in 2012, defines two perimenopausal stages: early perimenopause (Stage -2, cycle length varying ≥7 days from normal) and late perimenopause (Stage -1, one episode of amenorrhea ≥60 days). [1]

STRAW+10 Diagnostic Criteria

The STRAW+10 framework replaced earlier, less precise menopause staging definitions. Stage -2 begins when consecutive menstrual cycles start differing by 7 or more days. Stage -1 is entered when at least one cycle of 60 or more days occurs but 12 consecutive months of amenorrhea (menopause) have not yet been reached. [1]

FSH measured on cycle day 2 to 5 often exceeds 10 IU/L in early perimenopause and climbs above 25 IU/L in late perimenopause, but single readings vary widely. The Endocrine Society cautions that FSH alone cannot confirm perimenopause in women aged 40 to 45 and is not required for diagnosis in women over 45 with classic symptoms and cycle changes. [2]

Symptom Domains Requiring Treatment

Perimenopausal complaints span several domains that shape treatment selection:

• Vasomotor symptoms (VMS): hot flushes, night sweats
• Genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia, urgency
• Mood and cognitive symptoms: irritability, low mood, brain fog
• Menstrual irregularity: heavy or unpredictable bleeding
• Bone loss: accelerated trabecular bone resorption beginning 1 to 2 years before the final menstrual period

Knowing which domain is most troublesome drives line-of-therapy decisions more than any single biomarker.

First-Line Therapy: Lifestyle Measures and Patient Education

Before prescribing any medication, the 2023 Menopause Society Position Statement recommends structured lifestyle intervention as a foundation. These measures will not eliminate moderate-to-severe VMS but can meaningfully reduce symptom burden and cardiovascular risk. [3]

Behavioral and Lifestyle Interventions

A 2019 Cochrane review of lifestyle interventions for menopausal symptoms (28 RCTs, N=3,833) found that regular aerobic exercise reduced sleep disturbance and depressive symptoms but produced only modest effects on hot-flush frequency compared with control. [4] Specific evidence-based recommendations include:

• Aerobic exercise at least 150 minutes per week at moderate intensity (per AHA/ACC guidelines)
• Core temperature reduction strategies: layered clothing, cooling pillows, lowering ambient temperature
• Avoiding common VMS triggers: alcohol, spicy foods, and caffeine, each of which can raise core body temperature
• Smoking cessation, which independently advances the age of menopause by approximately 2 years

Cognitive Behavioral Therapy for VMS

Cognitive behavioral therapy (CBT) specifically targeting hot flushes and night sweats has the strongest non-pharmacological evidence. The MENOS 1 RCT (N=96) showed that group CBT reduced hot-flush problem rating by 42% versus 11% in controls (P<0.001). [5] The Menopause Society now lists CBT as a recommended non-hormonal option for women with mild-to-moderate VMS or for those who prefer to avoid medication. [3]

Second-Line Therapy: Hormonal Options

Hormone therapy remains the most effective treatment for perimenopausal VMS and GSM. In women without contraindications, it addresses multiple symptom domains simultaneously.

Low-Dose Combined Oral Contraceptives

For women in perimenopause who also need contraception (natural conception remains possible until 12 consecutive months of amenorrhea), low-dose combined oral contraceptives (COCs) containing 20 mcg ethinyl estradiol serve a dual purpose. The 20 mcg ethinyl estradiol/levonorgestrel formulation suppresses erratic ovarian activity, stabilizes cycles, and reduces VMS while providing reliable contraception. [6]

Contraindications that must be screened before prescribing COCs include:

• Active smoking in women aged 35 or older (WHO Medical Eligibility Criteria Category 4)
• Personal or strong family history of VTE
• Migraine with aura
• Uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg)
• Personal history of estrogen-sensitive malignancy

Menopausal Hormone Therapy: Estrogen Plus Progestogen

For perimenopausal women who do not need contraception or who cannot tolerate synthetic ethinyl estradiol, low-dose menopausal hormone therapy (MHT) using body-identical estradiol (oral 0.5 to 1 mg/day or transdermal 0.025 to 0.05 mg/day patch) plus a progestogen is the preferred second-line hormonal regimen. [3]

The choice between cyclic and continuous progestogen depends on stage:

• Early perimenopause (Stage -2): Cyclic progestogen (e.g., micronized progesterone 200 mg/day for 12 to 14 days per month) maintains menstrual cycling and reduces irregular bleeding.
• Late perimenopause (Stage -1): Either cyclic or continuous combined therapy is appropriate; continuous therapy (micronized progesterone 100 mg/day every day) is preferred when the woman is near menopause to avoid withdrawal bleeds.

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) demonstrated that low-dose oral conjugated equine estrogen (0.45 mg/day) and transdermal estradiol (50 mcg/day) both reduced VMS frequency by approximately 73% versus 51% on placebo over 4 years without increasing coronary artery calcium progression in recently menopausal women. [7]

Transdermal estradiol is associated with lower VTE risk than oral estrogen. A nested case-control study within the UK General Practice Research Database (N=15,710) found that transdermal estradiol did not increase VTE risk (OR 0.96, 95% CI 0.70 to 1.31), while oral estrogen doubled the risk (OR 2.07, 95% CI 1.51 to 2.84). [8]

Progestogen Selection and Endometrial Protection

Any woman with an intact uterus receiving systemic estrogen must receive adequate progestogen to prevent endometrial hyperplasia and cancer. The minimum endometrial-protective dose of micronized progesterone for cyclic use is 200 mg/day for 12 days per month; for continuous use, 100 mg/day is supported by the PEPI trial data. [9]

Synthetic progestins (medroxyprogesterone acetate, norethindrone acetate) are alternatives but carry a potentially less favorable breast and cardiovascular profile than micronized progesterone based on observational data. The Menopause Society 2023 Position Statement notes that micronized progesterone may carry a lower breast cancer risk signal compared with medroxyprogesterone acetate, though direct RCT comparison data are limited. [3]

Low-Dose Vaginal Estrogen for GSM

Genitourinary symptoms that persist despite systemic MHT, or as an isolated complaint in women who decline systemic therapy, respond well to low-dose local vaginal estrogen. Options include:

• Estradiol vaginal cream 0.01% (0.5 g 2 to 3 times per week)
• Estradiol vaginal tablet 10 mcg twice weekly
• Estradiol vaginal ring 7.5 mcg/24 h, replaced every 90 days

Systemic absorption from 10 mcg vaginal tablets is negligible (estradiol levels remain in the postmenopausal range <20 pg/mL). [10] Because systemic absorption is minimal, concomitant progestogen is generally not required for endometrial protection at this dose, per ACOG Practice Bulletin No. 141. [11]

Third-Line Therapy: Non-Hormonal Prescription Options

Women with contraindications to hormone therapy, hormone-sensitive malignancy history, or a strong personal preference against hormones have several evidence-based non-hormonal options.

SSRIs and SNRIs

Paroxetine mesylate 7.5 mg/day (Brisdelle) is the only FDA-approved non-hormonal treatment specifically for moderate-to-severe VMS. In a 24-week RCT (N=614), it reduced mean hot-flush frequency by 5.9 per day versus 3.9 per day on placebo (P<0.001). [12]

Other SSRIs and SNRIs used off-label include:

• Escitalopram 10 to 20 mg/day: reduced hot-flush frequency by 47% in a 9-week RCT (N=205) versus 29% on placebo. [13]
• Venlafaxine 37.5 to 75 mg/day: reduced VMS frequency by approximately 60% in short-term trials.
• Desvenlafaxine 100 to 150 mg/day: 26-week data showed 64% reduction versus 51% placebo in a 2008 RCT (N=458). [14]

Paroxetine should not be prescribed to women taking tamoxifen because it inhibits CYP2D6, impairing conversion of tamoxifen to its active metabolite endoxifen. Venlafaxine or escitalopram are preferred in that clinical scenario.

Fezolinetant: NK3 Receptor Antagonist

Fezolinetant (Veozah) 45 mg once daily was FDA-approved in May 2023, the first treatment in a new mechanistic class for VMS. It blocks neurokinin B signaling at NK3 receptors in the hypothalamic KNDy neurons, directly dampening the thermoregulatory firing that drives hot flushes.

The SKYLIGHT 1 and SKYLIGHT 2 Phase 3 trials (combined N=1,022) showed that fezolinetant 45 mg reduced mean daily moderate-to-severe hot-flush frequency by 60 to 65% at week 12 versus 45 to 50% on placebo, with statistically significant separation at week 4. [15] Liver enzyme elevations occurred in <1% of participants; baseline ALT and AST should be measured before starting therapy and monitored at 3 months.

Gabapentin and Pregabalin

Gabapentin 300 mg three times daily reduced hot-flush frequency by 45% versus 29% placebo in a 12-week RCT (N=59). [16] Sedation and dizziness are common at doses required for VMS control, limiting tolerability. Gabapentin is a reasonable option for women who also have comorbid neuropathic pain or sleep maintenance insomnia, where the sedating effect is desirable.

Clonidine

Oral clonidine 0.1 mg twice daily produces modest VMS reduction (approximately 20 to 40% from baseline) and carries a significant side-effect burden including dry mouth, constipation, and rebound hypertension on discontinuation. It is listed as a third-tier option in the Menopause Society guidance and should generally be reserved for women who cannot tolerate any of the above agents. [3]

Bone Protection: When to Screen and When to Treat

DXA Screening Triggers in Perimenopause

The USPSTF recommends DXA screening for women aged 65 and older, but also recommends screening for younger postmenopausal women whose 10-year fracture probability equals or exceeds that of a 65-year-old white woman with no additional risk factors (FRAX 10-year hip fracture risk ≥3%). [17]

Perimenopausal women with the following risk factors warrant earlier DXA:

• Low body weight (BMI <18.5 kg/m²)
• Current smoking
• Glucocorticoid use ≥3 months
• Rheumatoid arthritis
• Personal fracture history after age 40

Hormone Therapy as Bone Protection

MHT is FDA-approved for prevention of postmenopausal osteoporosis and is effective during perimenopause. The Women's Health Initiative (WHI, N=16,608) showed that continuous combined equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg reduced hip fracture risk by 34% (HR 0.66, 95% CI 0.45 to 0.98) over 5.2 years. [18]

For women already on MHT for VMS, fracture prevention comes without an additional prescription. For women using non-hormonal VMS therapy, adequate calcium (1,200 mg/day from diet plus supplement) and vitamin D3 (1,500 to 2,000 IU/day) remain the minimum bone-protective measures.

Managing Heavy Menstrual Bleeding in Perimenopause

Anovulatory cycles in perimenopause cause irregular, sometimes heavy bleeding that is distinct from postmenopausal bleeding and does not automatically require endometrial biopsy. An endometrial biopsy or transvaginal ultrasound is indicated when:

• Bleeding is unscheduled and persistent on MHT
• Endometrial thickness exceeds 4 mm on transvaginal ultrasound in a woman presenting with postmenopausal bleeding
• The woman is obese (BMI ≥30 kg/m²) with irregular bleeding, given the higher background risk of endometrial hyperplasia

The levonorgestrel intrauterine device (LNG-IUD, 52 mg) serves a dual role in perimenopause: it controls heavy menstrual bleeding and provides endometrial protection when used alongside systemic estrogen therapy, negating the need for oral progestogen. A 2021 Cochrane review (12 RCTs, N=1,013) confirmed LNG-IUD superiority over COCs and tranexamic acid for heavy menstrual bleeding reduction. [19] The ACOG Practice Bulletin No. 128 endorses LNG-IUD as a first-line medical option for heavy menstrual bleeding in women who want contraception or progestogen protection. [20]

Tranexamic acid 1,300 mg three times daily for up to 5 days per cycle reduces measured menstrual blood loss by 40 to 60% and is appropriate when bleeding control alone is needed without cycle regulation.

Mood and Cognitive Symptoms: Treatment Priorities

Distinguishing Perimenopausal Depression From Major Depressive Disorder

Perimenopausal depression is two to four times more common than depression in the stable reproductive years, based on data from the Penn Ovarian Aging Study (N=436, 10-year follow-up). [21] Symptoms often overlap with VMS-driven sleep disruption, making it difficult to determine whether mood is a primary target or a downstream consequence of poor sleep.

The American College of Obstetricians and Gynecologists recommends validated screening with the PHQ-9 at perimenopause-related visits. [22] A score of 10 or above warrants formal evaluation and may justify simultaneous treatment of both VMS and mood, where an SNRI such as venlafaxine 75 mg/day addresses both domains.

Hormone Therapy and Mood

Observational and RCT data suggest estrogen therapy has antidepressant-like properties specifically during perimenopause (but not after menopause). The PRISM RCT (N=172, transdermal estradiol 100 mcg versus placebo, 12 months) found that estradiol reduced PHQ-9 scores by 2.5 points more than placebo in perimenopausal women with depressive symptoms (P<0.05), while showing no effect in postmenopausal women. [23] This window of estrogen sensitivity reinforces starting MHT early in the perimenopausal transition for eligible women with comorbid mood symptoms.

Contraindications, Safety Considerations, and Monitoring

Absolute Contraindications to Systemic Hormone Therapy

Per the Menopause Society 2023 Position Statement [3]:

• Personal history of estrogen-receptor-positive breast cancer
• Active or recent (within 12 months) arterial thromboembolic event (MI, stroke)
• Active VTE or high-thrombotic-risk thrombophilia
• Active liver disease with elevated transaminases
• Unexplained vaginal bleeding pending evaluation

Relative Contraindications and Risk Stratification

Women with a first-degree family history of breast cancer, controlled hypertension, or treated hyperlipidemia are not excluded from MHT but require individualized counseling. The Menopause Society states: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture." [3]

Monitoring Schedule

| Parameter | Frequency | |---|---| | Blood pressure | Before initiation; at 3 months; then annually | | Mammography | Annually per ACR/ACS guidelines | | Endometrial assessment | Only if unscheduled bleeding occurs | | Lipid panel | Baseline; repeat at 1 year if oral estrogen used | | Liver function (fezolinetant users) | Baseline; 3 months; 6 months; then annually | | Bone density (DXA) | Per USPSTF risk-based criteria |

Putting the Algorithm Together: A Decision Map

The tiered framework below synthesizes Menopause Society, Endocrine Society, and ACOG guidance into a practical clinical sequence.

Step 1 (all patients): Confirm STRAW+10 stage. Screen for contraindications. Assess all symptom domains. Initiate lifestyle interventions (exercise, CBT, trigger avoidance).

Step 2A (hormones acceptable, contraception needed): Low-dose COC (20 mcg ethinyl estradiol) until cycle becomes reliably irregular or age 50 to 51, then transition to MHT.

Step 2B (hormones acceptable, no contraception needed): Transdermal estradiol 0.025 to 0.05 mg/day plus micronized progesterone 200 mg/day cyclically (Stage -2) or 100 mg/day continuously (Stage -1). Add 10 mcg vaginal estradiol if GSM persists.

Step 2C (MHT not preferred but hormones tolerated locally): Local vaginal estrogen only for isolated GSM. Non-hormonal systemic therapy for VMS.

Step 3 (hormones contraindicated or declined): Fezolinetant 45 mg/day (most efficacious non-hormonal option for VMS). Alternatively paroxetine 7.5 mg/day, escitalopram 10 mg/day, or venlafaxine 75 mg/day. Add gabapentin 300 mg TID for comorbid sleep disruption.

Step 4 (heavy menstrual bleeding): LNG-IUD 52 mg first-line if progestogen delivery and contraception both desired. Tranexamic acid for bleeding-only control. Endometrial biopsy before prescribing if risk factors for hyperplasia are present.

Step 5 (bone): Confirm calcium and vitamin D adequacy in all patients. DXA if FRAX ≥3% hip fracture probability or clinical risk factors. MHT counts toward fracture prevention if already prescribed.

Reassess every 12 months. No evidence supports an arbitrary 5-year maximum for MHT in perimenopausal women without contraindications; the Menopause Society explicitly states duration should be individualized. [3]